Ospemifene

Catalog No.S4285

Ospemifene is a non-hormonal selective estrogen receptor modulator (SERM), used for the treatment of dyspareunia.

Price Stock Quantity  
USD 97 In stock
USD 247 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Ospemifene Chemical Structure

Ospemifene Chemical Structure
Molecular Weight: 378.89

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare Estrogen/progestogen Receptor Chemicals
    Compare Estrogen/progestogen Receptor Products
  • Research Area

Product Description

Biological Activity

Description Ospemifene is a non-hormonal selective estrogen receptor modulator (SERM), used for the treatment of dyspareunia.
Targets Estrogen receptor [1]
In vitro
In vivo
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Portman DJ, et al. Menopause,2013,20(6):623-30.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02638337 Recruiting Vaginal Dryness Shionogi|Shionogi Inc. December 2015 Phase 3
NCT02784613 Recruiting Vulvovaginal Atrophy|Dyspareunia Sue Goldstein|San Diego Sexual Medicine July 2015 Phase 4
NCT00729469 Completed Atrophy|Vaginal Diseases Shionogi|Hormos Medical|QuatRx Pharmaceuticals|Shionogi Inc. July 2008 Phase 3
NCT00566982 Completed Atrophy|Vaginal Diseases Shionogi|Hormos Medical|QuatRx Pharmaceuticals|Shionogi Inc. October 2007 Phase 3
NCT00630539 Completed Atrophy|Vaginal Diseases Shionogi|Hormos Medical|QuatRx Pharmaceuticals|Shionogi Inc. August 2007 Phase 2

view more

Chemical Information

Download Ospemifene SDF
Molecular Weight (MW) 378.89
Formula

C24H23ClO2

CAS No. 128607-22-7
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 75 mg/mL (197.94 mM)
Ethanol 71 mg/mL warming (187.38 mM)
Water <1 mg/mL
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-ethanol

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Estrogen/progestogen Receptor Products

  • Licochalcone A

    Licochalcone A is an estrogenic flavanoid extracted from licorice root, showing antimalarial, anticancer, antibacterial and antiviral activities. Phase 3.

  • Endoxifen HCl

    Endoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.

  • LCZ696

    LCZ696, consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.

  • Fulvestrant

    Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

  • Tamoxifen Citrate

    Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding.

  • Mifepristone

    Mifepristone is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively.

    Features:Mifepristone is the first approved medication for patients with endogenous cushing's syndrome.

  • Raloxifene HCl

    Raloxifene is an estrogen antagonist, which inhibits human cytosolic aldehyde oxidase-catalyzed phthalazine oxidation activity with IC50 of 5.7 nM.

    Features:Raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk.

  • Estradiol

    Estradiol, or more precisely, 17β-estradiol, is a human sex hormone and steroid, and the primary female sex hormone.

  • Toremifene Citrate

    Toremifene Citrate is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.

  • Progesterone

    Progesterone is an endogenous steroid hormone involved in the menstrual cycle, pregnancy, and embryogenesis of humans and other species.

Recently Viewed Items

Tags: buy Ospemifene | Ospemifene supplier | purchase Ospemifene | Ospemifene cost | Ospemifene manufacturer | order Ospemifene | Ospemifene distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us